Skip to main content

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Western Blot

Cited:

Western Blot, Immunocytochemistry, Immunoprecipitation, ELISA Capture

Label

Unconjugated

Antibody Source

Polyclonal Sheep IgG

Product Specifications

Immunogen

E. coli-derived recombinant human Bcl9-2
Met38-Val206
Accession # Q86UU0

Specificity

Detects endogenous human Bcl9-2 in Western blots.

Clonality

Polyclonal

Host

Sheep

Isotype

IgG

Scientific Data Images for Human Bcl9-2 Antibody

Detection of Human Bcl9-2 antibody by Western Blot.

Detection of Human Bcl9-2 by Western Blot.

Western blot shows lysates of A172 human glioblastoma cell line and MCF-7 human breast cancer cell line. PVDF membrane was probed with 1 µg/mL of Human Bcl9-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4967) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for Bcl9-2 at approximately 190 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
Detection of Bcl9-2 by Western Blot

Detection of Bcl9-2 by Western Blot

BCL9L expression in primary pancreatic tumor tissue and cell lines(A) Box-and-whisker plot showing results from BCL9L mRNA expression analysis by qRT-PCR in tissue samples derived from primary human pancreatic tumors (n = 26 cases), chronic pancreatitis (n = 6 cases) and normal pancreas (n = 13 cases). Expression was normalized to ribosomal protein, large, P0 (RPLP0) mRNA levels. Bars represent median and 2nd and 3rd quartiles (boxes) as well as minimum and maximum values (whiskers). **p ≤ 0.01, ***p ≤ 0.001 (Student's t-test). (B) BCL9L mRNA levels in pancreatic cancer (8988t, IMIM PC1, IMIM PC2, MiaPaca-2, Panc1, S2-007, S2-028) and control (HEK 293) cell lines. (C) Staining of tissue microarrays (TMA) for BCL9L expression using immunohistochemistry. Enhanced expression was seen in PDAC tissues (bottom panels) compared to normal pancreas (upper panels). Staining intensity in PDAC tissues increased with tumor grade (bottom left: G1, bottom middle: G2, bottom right: G3). (D) BCL9L staining intensity of tissue microarrays was quantitatively evaluated and scored in normal and PDAC cases as described in Materials and Methods. Scores significantly increased with the progression to less differentiated PDAC (grade 2 and 3). ***p ≤ 0.001 (Mann-Whitney and Kruskal-Wallis non parametric test) (E) BCL9L protein expression in pancreatic cancer and control (HPNE) cell lines was quantified by western blotting. Detection of alpha-tubulin was used as a loading control. Shown is a representative image of 3 experiments. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/27713160), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human Bcl9-2 Antibody

Application
Recommended Usage

Western Blot

1 µg/mL
Sample: A172 human glioblastoma cell line and MCF-7 human breast cancer cell line

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Bcl9-2

Bcl9-2 (B-cell lymphoma 9-like protein; also Bcl9L and B9L) is a 200-220 kDa transcriptional regulator that belongs to the Bcl9 family of proteins. It is expressed in multiple tissues, particularly breast, and serves to recruit Pygopus to the Wnt-pathway beta-catenin-TCF complex in the nucleus. Bcl9-2 and Bcl9 are considered evolutionary duplicates of Legless that perform the same task with different regulation. Human Bcl9-2 is 1499 amino acids (aa) in length. It contains two Pro-rich regions (aa 280-493 and 891-1378). There are four potential alternate start sites at Met879, Met1000, Met708 and Met472. The last two start sites are accompanied by a deletion of aa 1241-1286, and a 62 aa substitution for the C-terminal 167 aa, respectively. Over aa 38-206, human Bcl9-2 is 94% aa identical to mouse Bcl9-2. Bcl9-2 has been identified as a phosphoprotein in several human cancer cell lines and mouse liver.

Long Name

B Cell Lymphoma/Leukemia 9-like Protein

Alternate Names

Bcl92, DLNB11

Entrez Gene IDs

283149 (Human); 80288 (Mouse); 300673 (Rat)

Gene Symbol

BCL9L

UniProt

Additional Bcl9-2 Products

Product Documents for Human Bcl9-2 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human Bcl9-2 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...